Update on Screening and Surveillance of Barretts Esophagus

To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.

Step Status
Video/Document(s)
Posttest
Evaluation
Starts On: 7/1/2021: 12:00 AM
Ends On: 6/30/2022: 12:00 AM
Session Type: Internet Activity Enduring Material
Credits: 0.75
Description:

Faculty

Srinadh Komanduri, MD, MS
Professor of Medicine, Division of Gastroenterology and Hepatology
Professor of Surgery, Division of Gastrointestinal Surgery
Northwestern Medicine, Feinberg School of Medicine, Chicago, Illinois
Financial Relationships
Consulting/Advisory Committees: Boston Scientific, Medtronic

Planning Committee

Vladimir M. Kushnir, MD, FASGE
Associate Professor of Medicine, Course Chair
Financial Relationships
- Speakers Bureau/Honoraria: Aspire Bariatrics, Boston Scientific Corporation,
- Consulting/Advisory Committees: Cook Medical Inc, GLG Group, Motis GI, Medtronic (Ireland),
- Research Support/Grants: Motus GI Holdings

Gabriel D. Lang, MD
Assistant Professor of Medicine, Co- Chair
Financial Relationships
Research Support/Grants: Cook Medical Inc

Eric Ruettgers, MSN, RN, ANP-BC
Adult Nurse Practitioner
Division of Gastroenterology/Endoscopy Barnes-Jewish West County Hospital
Financial Relationships: Nothing to disclose


Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, 1st Annual Mid-West Virtual Therapeutic Endoscopy, August 29, 2020, which was supported in part by Cook Medical, LLC.
Objectives: The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
  • Discuss current limitations in reducing deaths from esophageal adenocarcinoma.
  • Review the limitations of the current management of patients with Barrett's Esophagus.
  • Summarize new innovation for endoscopic surveillance and risk stratification of Barrett's
    Esophagus.
  • Discuss the current effectiveness of endoscopic eradication therapy and reasons for recurrence.
  • Discuss the current status and innovation for screening for Esophageal cancer and BE.
Additional Information:
Target Audience: This course is designed for gastroenterologists, surgeons, primary care physicians, residents, fellows, advanced practice nurses and physician assistants.
Accreditation Information:
wustlcme
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Awarded for this Activity:
Credit Statement: American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 ANCC contact hour.
References:
  • Kong CY. Cancer Epidemiol Biomarkers Prev 2014;23:997 Courtesy of Stu Spechler.
  • Vakil N et al. Am J Gastroenterol 2006;101:1900, Eusebi LH et al, Gut 2020, Sawas T et al., CGH 2019
  • Qumseya B et al., ASGE Standards of Practice 2019
  • Wani S et al., Clinical Gastro and Hep 2020
Disclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
All members of the CME department have nothing to disclose.

Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.

These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.


Powered By AI 4.5